Virtual Library
Start Your Search
Ibrahim Tek
Author of
-
+
P2.03 - Biology (Not CME Accredited Session) (ID 952)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 2
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.03-06 - Serum Syndechan-1 Levels in Patients with Nonsmall Cell Lung Cancer (ID 12088)
16:45 - 18:00 | Presenting Author(s): Ibrahim Tek
- Abstract
Background
Cytokines as polypeptide or glycopeptide molecules are the essential mediators of immune response and the inflammatory reactions in addition to numerous biological reaction they are involved in. Syndecans have an important role in a variety of cellular functions including cell proliferation and migration, and cell- /cell and cell-/matrix interactions. Syndechan-1 is a transmembrane heparan sulphate proteoglycans that is present on most cell types. In this study we aimed to evaluate the levels of syndecan-1, levels in non-small cell lung cancer (NSCLC), and to evaluate their relationship with tumor progression.
a9ded1e5ce5d75814730bb4caaf49419 Method
Sixtysix patients (F=3, M=63) with non-small cell lung cancer and 22 healthy (F=3, M=19) subject were enrolled this study. Patients with infections or other systemic disease were not included in the study. Serum levels of syndecan-1 was measured by ELISA system. Serum samples were obtained from each patient before the initiation of any type cancer treatment. They were centrifuged at 3000 rpm for 10min, and then stored at -70°C. Unpaired t-test was used to compare continuous variables between the patient group and control group and within the patient group according to TNM classification. Correlation analysis between cytokines and tumor stage was performed using the Pearson correlation coefficient. Sensitivity, specificity, positive predictive value and negative predictive values for syndecan-1 were determined using receiver operator characteristic analysis (ROC). These analyses were done to define clinically valid cutoff points to predict distant metastasis. A two-sided p values less than 0.05 was considered to be statistically significant.
4c3880bb027f159e801041b1021e88e8 Result
Serum levels of syndecan-1 in patients with NSCLC were significantly higher than those of controls (p<0.001). In addition, mean levels of synde- can-1 in stage IV disease were significantly higher than non-metastatic NSCLC (p<0.001). In the patients with only one distant metastasis, levels of syndecan- 1 were found to be lower than those of the patients with multiple distant metastases. Syndecan-1 has high sensitivity (78%), specificity (91%), positive (88%) and negative predictive (80%) values for prediction of metastasis.
8eea62084ca7e541d918e823422bd82e Conclusion
In conclusion, we found that syndecan-1 changes significantly in serum of patients with NSCLC. In our study, these changes correlated well with the stage of lung cancer. Syndecan-1 with a high sensitivity, specificity and positive predictive value may be used in predicting the presence and nature (single or multiple) of metastasis. The authors believe that the current findings will provide clinicians with new insights, allowing them to implement more individualized treatment strategies in patients with lung cancer.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P2.03-34 - The Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer (ID 12081)
16:45 - 18:00 | Presenting Author(s): Ibrahim Tek
- Abstract
Background
Early diagnosis and the improvement in the treatment options in cancer patients can prolong the survival in the majority of malignancies, although they add no benefit to the survival of patients with non-small cell lung cancer (NSCLC). Some patients with NSCLC respond to the treatment well while others do not. Therefore, new prognostic factors and biomarkers other than the stage of disease should be explored in NSCLC. The management of NSCLC may be different according to those biomarkers. The new biomarkers may help to the clinicians to identify who patients have poor prognosis and respond to the specific treatment.
a9ded1e5ce5d75814730bb4caaf49419 Method
The aim of this study is to investigate whether there is a relationship between the response to treatment and serum level of active EGFR or not. Thirty-three patients with locally advanced, metastatic or recurrent non-small cell lung cancer were enrolled into this study. Cisplatin docetaxel treatment was planned for those patients. Baseline and at the end of second and forth cycle of the treatment, serum EGFR were measured. Patients were divided into 2 groups according to their response to the treatment.SPSS7.0 was used to analyse patient data. Student t test and Mann-Withney U tests were used for the comparison between the groups' averages. Spearmann rho and Ki square tests were used to evaluate the relationships between parameters. Kaplan-Meier method was used for the survival analysis.
4c3880bb027f159e801041b1021e88e8 Result
Of 33 patients, 4 were female and 29 were male. The average of age of patients was 52. 12 patients were stage III, 21 were relapsed or stage IV. Objective response rate and overall response rate were found 15.6%, 34.4% respectively. Progression occurred 34.4% among patients in the study. When serum EGFR level cut off is 0.080 fmol/ml, while in patients who didn't respond, the positivity of serum EGFR level was 55.6%, it was 80% in patients who responded. Baseline serum EGFR levels were higher in patients with stage III disease compared to those of patients with relapsed and stage IV disease. In patients who responded to the therapy, baseline serum EGFR levels were found higher than those of the patients who didn’t respond regardless of the stage. Following two cycles of treatment, if serum EGFR level is found high, then the probability to respond to the treatment increases significantly.
8eea62084ca7e541d918e823422bd82e Conclusion
In conclusion, the serum level of EGFR seems to be a useful biomarker for predicting and monitoring the response to the treatment in patients with NSCLC.
6f8b794f3246b0c1e1780bb4d4d5dc53